Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Cautions Investors Over Sell-Side Analysts' Estimates

This article was originally published in The Pink Sheet Daily

Executive Summary

Following a surge in trading volume due to Carl Icahn's clearance to purchase up to 11.9% of Mylan stock, the company says that analysts' estimates may not reflect negative changes in the generic industry. Mylan plans to provide guidance "as soon as practically possible."
Advertisement

Related Content

Mylan’s Duragesic Generic Cannot Escape J&J’s Pediatric Exclusivity – Court
Mylan Sues FDA, Seeks Injunction Against Macrobid “Authorized” Generic
“Authorized” Generics Fight Moves To Capitol Hill, FTC
J&J Duragesic Pediatric Exclusivity Keeps Mylan Fentanyl Patch Off The Market Until January
J&J Duragesic Pediatric Exclusivity Keeps Mylan Fentanyl Patch Off The Market Until January

Topics

Advertisement
UsernamePublicRestriction

Register

PS060359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel